Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. However, most patients with osimertinib treatment eventually relapse within one year. The underlying me...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shaocong, Luo, Min, To, Kenneth K. W., Zhang, Jianye, Su, Chaoyue, Zhang, Hong, An, Sainan, Wang, Fang, Chen, Da, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812728/
https://www.ncbi.nlm.nih.gov/pubmed/33461557
http://dx.doi.org/10.1186/s12943-021-01307-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812728/
https://www.ncbi.nlm.nih.gov/pubmed/33461557
http://dx.doi.org/10.1186/s12943-021-01307-9

Ejemplares similares